CD47 and neoplasm: In vitro studies in CRC cell lines and in vivo xenograft models have shown that genetic or pharmacological modulation of CD47 can suppress tumor growth and metastatic potential, even under immune cell-depleted conditions, highlighting tumor-intrinsic vulnerabilities [91].